Smart system helps nurses and doctors stop dangerous low blood sugar in its tracks
NCT ID NCT07314749
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a team of doctors and nurses, guided by an intelligent early-warning system, could reduce low blood sugar (hypoglycemia) in hospitalized adults with type 2 diabetes. Over 1,200 participants received either standard insulin pump therapy or the same therapy plus the collaborative intervention, which included personalized insulin adjustments and risk-based education. The goal was to see if the smart system could help prevent hypoglycemia and help patients reach their blood sugar targets faster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Physician-nurse collaborative intervention guided by an intelligent hypoglycemia risk early-warning system
What this could lead to
If successful, this approach could help hospitals prevent dangerous low blood sugar episodes and help patients with type 2 diabetes reach their blood sugar targets faster during insulin pump therapy.
What could go wrong
This is a completed study, but its findings may not apply to all diabetes patients, especially those not hospitalized or on different treatments. The intelligent system's accuracy and generalizability need further validation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Third Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510630, China